|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Institute of Mental Health (NIMH) |
|---|---|
| Information provided by: | National Institute of Mental Health (NIMH) |
| ClinicalTrials.gov Identifier: | NCT00441649 |
Purpose
This study will evaluate the safety and effectiveness of methylphenidate in treating attention deficit hyperactivity disorder in children with both attention deficit hyperactivity disorder and Tourette syndrome.
| Condition | Intervention |
|---|---|
|
Attention Deficit Disorder With Hyperactivity Tourette Syndrome |
Drug: Methylphenidate |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Methylphenidate Treatment of ADHD in Children With Tourette Syndrome |
| Estimated Enrollment: | 71 |
| Study Start Date: | February 2000 |
| Study Completion Date: | January 2007 |
| Primary Completion Date: | June 2004 (Final data collection date for primary outcome measure) |
Tourette syndrome is a neurological disorder that is characterized by repetitive, involuntary movements and vocalizations called tics. Many children with Tourette syndrome also have attention deficit hyperactivity disorder (ADHD), which is one of the most common childhood mental disorders. Symptoms of ADHD usually include impulsiveness, inattention, and hyperactivity. ADHD is commonly treated with a stimulant medication, such as methylphenidate. It is under debate, however, whether using stimulants in children with Tourette syndrome exacerbates tics associated with the disorder. This study will evaluate the safety and effectiveness of methylphenidate in treating ADHD in children who have both ADHD and Tourette syndrome.
Participants in this 6-week, double blind study will receive three doses of methylphenidate over the course of the study. Each dose will be taken twice daily, approximately 3.5 hours apart, for 2 weeks. Medication will be dispensed at study visits, which will occur once every 2 weeks. At each study visit, participants will take a dose of the medication. About an hour after ingesting the medication, they will be observed in a classroom setting by study physicians. Participants will then complete a Continuous Performance Test, which will measure their voluntary attention levels. The following will be assessed at study visits: ADHD symptoms; oppositional and aggressive behavior; frequency and severity of tics and obsessive compulsive disorder symptoms; rebound tic exacerbation; effects of methylphenidate on tic-related problems with self-esteem, family life, academic and social performance, and overall tic severity; anxiety and mood symptoms; and adverse drug reactions. Parents and teachers will also complete assessments of participants' behavior on 2 days of each week for the duration of the study.
Eligibility| Ages Eligible for Study: | 6 Years to 12 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | R01 MH45358, DDTR B2-NDH |
| Study First Received: | February 28, 2007 |
| Last Updated: | March 3, 2008 |
| ClinicalTrials.gov Identifier: | NCT00441649 History of Changes |
| Health Authority: | United States: Federal Government |
|
ADHD |
|
Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Basal Ganglia Diseases Methylphenidate Brain Diseases Neurodegenerative Diseases Signs and Symptoms Heredodegenerative Disorders, Nervous System Pathologic Processes Attention Deficit Disorder with Hyperactivity Movement Disorders Mental Disorders |
Therapeutic Uses Syndrome Mental Disorders Diagnosed in Childhood Hyperkinesis Disease Nervous System Diseases Central Nervous System Diseases Attention Deficit and Disruptive Behavior Disorders Central Nervous System Stimulants Tourette Syndrome Tic Disorders Dyskinesias Pharmacologic Actions Genetic Diseases, Inborn Neurologic Manifestations |